Hexagon shaped overlay

R&D insights: The covalent inhibitor revolution

5
min read

Historically, covalent inhibitors were avoided due to toxic side effects, but the latest breakthroughs in targeting have created a new landscape of opportunities. New breakthrough drugs like ibrutinib, sotorasib, and afatinib are reshaping the landscape of covalent inhibitors. For leaders of R&D, this idea in brief highlights key players, forces, and publication trends that enable better navigation of the opportunities ahead.

fanned image

Download the executive report

Gain new perspectives for faster progress directly to your inbox.